On May 21, 2024, Biocon Ltd informed the stock exchanges that the United States Food and Drug Administration (US FDA) had approved its first-to-file application for Yesafili (aflibercept – jbvf), an interchangeable biosimilar aflibercept. YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor used to treat various ophthalmologic conditions, is a biosimilar to its reference product, …